Form 4: Abbott Laboratories Executive Receives Significant Equity Awards

Elizabeth C. Cushman, EVP, General Counsel, and Secretary of Abbott Laboratories, was granted 3,790 performance-based restricted stock units and 14,680 stock options on June 27, 2025.

Summary

• Elizabeth C. Cushman, an Executive Vice President, General Counsel, and Secretary at Abbott Laboratories, acquired 3,790 common shares without par value on June 27, 2025.
• These shares are part of a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program.
• The restricted stock award has a 3-year term, with vesting of no more than one-third of the award annually, contingent upon Abbott reaching a minimum return on equity target.
• Cushman also acquired 14,680 employee stock options on June 27, 2025, with an exercise price of $133.9 per share.
• These options were granted under the Abbott Laboratories 2017 Incentive Stock Program and become exercisable in annual increments: 4,893 options on June 27, 2026; 4,893 options on June 27, 2027; and 4,894 options on June 27, 2028.
• The options have an expiration date of June 26, 2035.
• Following these transactions, Cushman beneficially owns 25,226 common shares and 14,680 derivative options.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, aligning executive incentives with company performance through equity awards. This is generally viewed positively as it promotes long-term value creation, with no negative or unexpected elements.

Positives

• Grants of performance-based restricted stock and stock options align executive incentives with shareholder value creation.
• The performance-based vesting for restricted stock, tied to a minimum return on equity target, encourages strong financial performance.
• The stock option grant provides a long-term incentive for the executive, with an expiration date extending to 2035.

Risks

• The vesting of the performance-based restricted stock award is contingent on Abbott Laboratories achieving a minimum return on equity target, meaning the full award may not vest if performance targets are not met.

Future Outlook

The document details future vesting schedules for equity awards, indicating a long-term incentive structure for the executive. The performance-based nature of the restricted stock award suggests a focus on achieving specific financial targets, such as return on equity, in the coming years.

Industry Context

The granting of performance-based restricted stock and stock options is a standard practice in the pharmaceutical and medical device industry, like Abbott Laboratories, to incentivize executive performance and align their interests with long-term shareholder value. Such compensation structures are common across large, established companies to attract and retain top talent.

Comparison to Industry Standards

• Executive equity compensation, particularly through performance-based restricted stock and stock options, is a widely adopted practice across global healthcare and consumer staples companies.
• While specific award sizes and vesting conditions vary, the structure seen at Abbott Laboratories aligns with typical incentive programs at peers such as Johnson & Johnson, Medtronic, or Pfizer, which also utilize long-term equity incentives tied to financial performance metrics like ROE or total shareholder return.

Corporate Governance

Related Party Transactions

• The transactions involve the grant of equity awards from Abbott Laboratories to a senior executive, Elizabeth C. Cushman, which are standard related-party transactions in the context of executive compensation.

Stakeholder Impact

• Shareholders: The equity awards align the executive's interests with shareholders by tying compensation to company performance (e.g., return on equity), potentially encouraging long-term value creation.
• Employees: The incentive program may signal the company's commitment to performance-based rewards, potentially influencing broader employee compensation strategies.

Next Steps

• Continued monitoring of Abbott Laboratories' financial performance, particularly its return on equity, to assess the vesting potential of the restricted stock award.
• Observation of future Form 4 filings for Elizabeth C. Cushman to track changes in her beneficial ownership.

Key Dates

Recommendation

Keywords

Abbott Laboratories, ABT, SEC Form 4, Insider Trading, Stock Award, Stock Option, Restricted Stock Unit, Executive Compensation, Performance-based Award, Equity Grant, Elizabeth C. Cushman